Michigan Institute for Clinical and Health Research, School of Public Health, School of Medicine, University of Michigan, Ann Arbor, MI, USA.
Eval Health Prof. 2013 Dec;36(4):478-91. doi: 10.1177/0163278713499587. Epub 2013 Aug 7.
Assessing the value of clinical and translational research funding on accelerating the translation of scientific knowledge is a fundamental issue faced by the National Institutes of Health (NIH) and its Clinical and Translational Awards (CTSAs). To address this issue, the authors propose a model for measuring the return on investment (ROI) of one key CTSA program, the clinical research unit (CRU). By estimating the economic and social inputs and outputs of this program, this model produces multiple levels of ROI: investigator, program, and institutional estimates. A methodology, or evaluation protocol, is proposed to assess the value of this CTSA function, with specific objectives, methods, descriptions of the data to be collected, and how data are to be filtered, analyzed, and evaluated. This article provides an approach CTSAs could use to assess the economic and social returns on NIH and institutional investments in these critical activities.
评估临床和转化研究资金在加速科学知识转化方面的价值，是美国国立卫生研究院（NIH）及其临床和转化奖（CTSAs）面临的一个基本问题。为了解决这个问题，作者提出了一种衡量关键 CTSA 项目之一——临床研究单位（CRU）投资回报率（ROI）的模型。通过估计该计划的经济和社会投入和产出，该模型产生了多个层次的 ROI：研究人员、计划和机构的估计。本文提出了一种方法或评估协议，以评估该 CTSA 功能的价值，包括具体目标、方法、要收集的数据描述以及如何筛选、分析和评估数据。本文为 CTSA 提供了一种评估 NIH 和机构在这些关键活动中投资的经济和社会效益的方法。
